Switch from an oral antipsychotic to a long-acting injectable antipsychotic was associated with better treatment persistence and lower risk of treatment discontinuation than a switch from an oral antipsychotic to another oral antipsychotic in a real-world cohort of German patients with schizophrenia.

Patients suffering from comorbidities also had a higher risk of treatment discontinuation.